Nifty Corporate Earnings Analysis –
Q4 | 2016
by Rajat Sharma | May 12, 2016
Yesterday we analyzed earnings trend for constituent companies of the S&P CNX Nifty. On year-on-year basis (Q4 2015 to Q4 2016) corporate earnings showed a growth of 14.7%. In comparison, average stock prices went down by 1.9% during the same period*.
* Based on stock prices as on 31st March for each year.
** Based on 26 of the 50 companies comprising the S&P CNX Nifty that have declared results as of the date of this article.
Current PE Valuation of the Nifty = 21.30
Excel Calculation – 26 Nifty Company Result
Key Points about Corporate Earnings for Q4:
- The analysis is based on the results of 26 out of 50 Nifty companies which have declared earnings so far.
- Note – from April 1, 2016, Nifty has excluded Cairn, Vedanta, and PNB and included Aurobindo Pharma, Bharti Infratel, and Eicher Motors
- Earnings are improving while stock prices are showing a declining trend.
- On year-on-year basis there is an average growth of 14.7% in profitability. The benchmark Nifty went down 9 % in the same period.
- On a trailing basis markets remain expensive and are trading at valuations of 21.30 (PE).
- Most sectors have shown considerable improvement in profitability.
- Fundamentally (besides valuations) things are looking good at macro level.
- Pharma, Metals, Construction, Oil and Gas , Power companies are yet to announce their earnings for Q4 of FY 2016.
WE WILL BE UPDATING THIS ARTICLE ONCE REST OF THE COMPANIES DECLARE THEIR RESULTS OVER THE NEXT 1 MONTH.
BOOKMARK THIS SPACE.
Share this post
Don’t forget to leave a comment
Don’t forget to leave a comment
Other Posts
Other Posts
Aarti Drugs Stock Analysis
Aarti Drugs Limited (“Aarti Drugs” or the “Company”) is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary – Pinnacle Life Science Private...
Do PSU Stocks Offer Great Value?
The BSE PSU stocks index has massively underperformed the benchmark S&P BSE Sensex in the past five years. While the BSE Sensex has appreciated 49.4% (from 27079.51 to 40433.52), the BSE PSU Index has fallen 34.7% (from 6955.32 to 4535.22). The BSE Sensex now...
IPCA Laboratories Stock Analysis
IPCA Laboratories Limited (“IPCA” or the “Company”) is one of the world’s largest manufacturers and suppliers of over a dozen APIs. The Company’s product range includes pain management, cardiovascular medicines, anti-malarial, anti-emetic, antibiotic, analgesic, and...
Free Investment Newsletter
Join us and connect with over 65,000 subscribers who benefit from our insights on the latest
in the world of stocks and personal finance.
Free Investment Newsletter
Join us and connect with over 65,000 subscribers who benefit from our insights on the latest
in the world of stocks and personal finance.
0 Comments